louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01960088: Adolescent Vaccination in Pharmacies
Official title: Building Evidence to Expand Adolescent Vaccination in Pharmacies
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Evaluating Attitudes Toward HPV Vaccinations in Pharmacies
Evaluating the Provision of HPV Vaccines in a Pharmacy
Keywords: Adolescent vaccines
HPV vaccine
Pharmacies
Lead sponsor: University of North Carolina, Chapel Hill
Sponsor class: OTHER
Collaborators: name: Merck Sharp & Dohme LLC
First posted: 2013-10-10
Enrollment: 1509
Sex: ALL
Minimum age (years): 11
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: National survey: Parents of adolescents ages 11-18. Pharmacy sample: Parents of adolescent boys and girls, ages 11-18 whose families reside in the Chapel Hill area, and their adolescents.

Brief summary: The study aims to expand the evidence supporting pharmacy provision of adolescent vaccines, including human papillomavirus (HPV) vaccine. In the first part of the study, we will characterize parents' attitudes and support for pharmacy provision of adolescent vaccines in a national survey. In the second part of the study, we will provide HPV vaccines and other vaccines (Tdap, meningococcal, varicella, influenza) to 200 adolescents in a local community pharmacy in Chapel Hill, North Carolina. This portion of the study will identify the systems and workflow needed to provide vaccines effectively and safely, characterize parents' and their adolescents' attitudes toward receiving vaccine services in a pharmacy, and characterize pharmacists' attitudes toward providing adolescent vaccine services in a pharmacy.


Eligibility criteria: NATIONAL SURVEY (probability sample)

Inclusion Criteria:

* Being a member of the GfK Knowledge Panel
* Having a child age 11-18.

Exclusion Criteria:

● None

PHARMACY DEMONSTRATION PROJECT (convenience sample)

Inclusion Criteria:

* Having an adolescent child, ages 11-18 years old, who is healthy, and for whom HPV vaccine is indicated
* Child is with the parent

Exclusion Criteria:

● Being the parent of an adolescent who is immunocompromised, or has other chronic illness, has known anaphylactoid/hypersensitivity reactions to components of HPV vaccine used, or is pregnant or plan to be pregnant within a month of vaccination.

Primary outcomes:
measure: Parents' willingness to get their adolescent children HPV vaccine in pharmacy
timeFrame: At time of study
measure: Parents' satisfaction with HPV vaccine vaccine administration in the pharmacy
timeFrame: At time of vaccine administration
Secondary outcomes:
Other outcomes:
Locations:
city: Durham
country: United States
facility: Central Pharmacy
state: North Carolina
city: Durham
country: United States
facility: Triangle Pharmacy
state: North Carolina
Study officials:
affiliation: University of North Carolina, Chapel Hill
name: Noel T Brewer, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04167488: Assessment of Physical Activity Among Juvenile Idiopathic Arthritis Children Performed With Actigraphy
Official title: Assessment of Physical Activity Among Juvenile Idiopathic Arthritis Children Performed With Actigraphy
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Juvenile Idiopathic Arthritis
Lead sponsor: Centre Hospitalier Universitaire de Besancon
Sponsor class: OTHER
First posted: 2019-11-19
Enrollment: 50
Sex: ALL
Minimum age (years): 4
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: This study aims to describe physical activity among juvenile idiopathic arthritis children, according to the disease's and patient's characteristics.


Eligibility criteria: Inclusion Criteria:

* Juvenile idiopathic arthritis evolving for more than a year

Exclusion Criteria:

* intra-articular infiltration performed less than a month ago

Primary outcomes:
measure: Physical activity assessment
timeFrame: Day 7
Secondary outcomes:
Other outcomes:
Locations:
city: Besançon
country: France
facility: CHU de Besançon
Study officials:
affiliation: CHU de Besançon
name: Claire BALLOT SCHMIT, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00234988: A Phase IV, Multi-Center, Open-Label Trial of Sibutramine in Combination With a Hypocaloric Diet in Obese and Overweight Thai Subjects.
Official title: Safety and Weight Reduction of Sibutramine in the Treatment of Thai Obese and Overweight Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Obesity
Keywords: Sibutramine
Obesity
Lead sponsor: Abbott
Sponsor class: INDUSTRY
First posted: 2005-10-10
Enrollment: 93
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of the study is to determine the safety and weight loss when sibutramine is used in overweight and obese subjects.


Eligibility criteria: Inclusion Criteria:

* Subject has nutritional obesity and BMI \>30 kg/m

Exclusion Criteria:

* Type 1 or type 2 diabetes mellitus
* Inadequately controlled hypertension
* History of Gilles de la Tourette's Syndrome.
* Use of any MAOIs, SSRIs, amino acids, antimigraine drugs, opioids
* Hypothyroidism or hyperthyroidism.
* History of:

  * benign prostatic hyperplasia
  * neurological disorders
  * psychiatric illness
  * severe renal or hepatic impairments
  * narrow-angle glaucoma
* History of cardiovascular disease or cerebrovascular disease
* Persistent tachycardia at rest
* Pulmonary hypertension
* Phaeochromocytoma

Primary outcomes:
measure: Weight loss
timeFrame: 48 weeks
measure: Safety parameters
timeFrame: 48 weeks
Secondary outcomes:
measure: Waist and hip circumference
timeFrame: 48 weeks
measure: Fasting glucose
timeFrame: 48 weeks
measure: Fasting lipids
timeFrame: 48 weeks
measure: Uric acid
timeFrame: 48 weeks
Other outcomes:
Locations:
city: North Chicago
country: United States
facility: Global Medical Information - Abbott
state: Illinois
Study officials:
affiliation: Abbott
name: Global Medical Information 1-800-633-9110
role: STUDY_DIRECTOR
References:
Clinical trial NCT01764178: Pharmacokinetic Study of Livalo® Fixed Combination Drug in Healthy Subjects
Official title: A Single Dose, Sequence-randomized, Open-label, 2x2 Crossover Study to Compare Pharmacokinetics Between Pitavastatn and Valsartan Co-administration and Livalo Complex Product in Healthy Male Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Hyperlipidemia
Hypertension
Keywords: Pitavastatin
Valsartan
Lead sponsor: JW Pharmaceutical
Sponsor class: INDUSTRY
First posted: 2013-01-09
Enrollment: 52
Sex: MALE
Minimum age (years): 20
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: OTHER

Brief summary: The purpose of this study is to compare pharmacokinetics between Pitavastatin and Valsartan co-administration and Livalo fixed combination drug in healthy male subjects.


Eligibility criteria: Inclusion Criteria:

* Healthy male volunteers
* Age 20-55 years at the time of Screening
* BMI 19-26 kg/m2 at the time of Screening

Exclusion Criteria:

* Received other investigational drug within 90 days prior to the first dose of study drug

Primary outcomes:
measure: Cmax and AUC of study drugs after single oral administration
timeFrame: 0-48hrs
Secondary outcomes:
measure: AUCinf of study drugs after single oral administration
timeFrame: 0-48hrs
measure: t1/2β of study drugs after single oral administration
timeFrame: 0-48hrs
measure: Tmax of study drugs after single oral administration
timeFrame: 0-48hrs
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Asan Medical Center
Study officials:
affiliation: Asan Medical Center
name: Kyun Seop Bae, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00520078: Clinicopathological and Molecular Correlation of Acrochordon in Relation to Human Papillomavirus Infection
Official title: Clinicopathological and Molecular Correlation of Acrochordon in Relation to Human Papillomavirus Infection
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Acrochordon
Skin Tag
Soft Fibroma
Human Papillomavirus
HPV
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
Collaborators: name: National Science and Technology Council, Taiwan
name: National Health Research Institutes, Taiwan
First posted: 2007-08-23
Enrollment: 100
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: OTHER

Brief summary: Acrochordon, or soft fibroma, is a common benign skin tumor which is generally regarded as a sign of cutaneous aging or as a reaction to friction since it occurs in the intertriginous areas. Recent studies have shown the presence of human papillomaviruses, especially the mucosal types, on some of the intertriginous lesions. This study is to analyze the different clinical presentations of acrochordon and correlate them with pathologic and molecular human papillomavirus findings. Further goal is to improve the ability to differentiate acrochordon and its possible prevention and treatment. Also, it may have an implication on the transmission and prevention of cervical carcinoma.

Detailed description: Acrochordon, also called soft fibroma, skin tag or fibroepithelial polyp, is a common cutaneous disorder characterized by a polypoid growth composed of fibroblasts in a loose collagenous stroma, sometimes with proliferation of blood vessels. They appear as soft, skin-colored or light brownish skin tumors. Three types of lesions may occur, (1) multiple small, furrowed papules, especially on the neck and in the axillae, (2) single or multiple filiform smooth growths in various locations, and (3) solitary bag-like pedunculated growth, seen most commonly on the lower trunk. Most regard them as a sign of cutaneous aging.

The presence of human papillomaviruses (HPVs), especially the mucosal types, has been demonstrated in acrochordon. Our previous experience on HPV typing of skin tags also confirms this finding. Though HPV is a ubiquitous virus, the presence of mucosal type HPV in non-mucosal sites is exceptional. This investigation is trying to correlate the clinicopathological and HPV molecular typing of acrochordons. A better understanding of acrochordon and its relation to HPV infection may improve the ability to prevent and treat.

Eligibility criteria: Inclusion Criteria:

* Adult patients with multiple acrochordon on non-anogenital sites who ask to remove the lesions and have signed consent to surgery will be asked to participate in the study

Exclusion Criteria:

* No special exclusion criteria

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: National Taiwan University Hospital
Study officials:
affiliation: National Taiwan University Hospital
name: Tsen-Fang Tsai, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06545578: Effect of Motor Control Exercise Combined With Laser Or TENS on Pain, Range of Motion, and Functional Disability on Obese Patients With Low Back Pain
Official title: Effect of Motor Control Exercise Combined With Laser Or TENS on Pain, Range of Motion, and Functional Disability on Obese Patients With Low Back Pain
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Back Pain
Obesity
Motor Control Exercises
Laser Therapy
Lead sponsor: Ahram Canadian University
Sponsor class: OTHER
First posted: 2024-08-09
Enrollment: 60
Sex: ALL
Minimum age (years): 40
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This randomized study aimed to assess the impact of MCE in conjunction with LLLT and MCE in conjunction with TENS on pain levels, ROM, and functional disability in obese patients with LBP.

Detailed description: Sixty obese male and female patients with LBP participated in this study. After providing informed consent, they were randomly divided into two equal groups, with Group A receiving MCE combined with LLLT and Group B receiving MCE combined with TENS.

Eligibility criteria: Inclusion Criteria:

The inclusion criteria were the following:

* patients aged 40 to 77 years
* non-athletic, have a BMI \> 25
* complaining of LBP.

Exclusion Criteria:

The exclusion criteria were the following:

* vertebral fractures
* surgical spinal fixation
* rheumatic disorders
* any underlying medical condition that may be causing back pain, including:
* malignancy
* viscerogenic causes
* infection, systemic disease of the muscles and skeletal system,
* sensory dysfunction
* neuromuscular diseases like multiple sclerosis.

Primary outcomes:
measure: The pain was evaluated utilizing the visual analog scale (VAS)
timeFrame: before treatment and 4 weeks after treatment
measure: the functional disability, the Oswestry disability questionnaire version 2.0
timeFrame: before treatment and 4 weeks after treatment
measure: 1- Assessment of lumbar flexion ROM
timeFrame: before treatment and 4 weeks after treatment
measure: 2- Assessment of lumbar extension ROM
timeFrame: before treatment and 4 weeks after treatment
measure: 3- Assessment of lumbar side bending ROM
timeFrame: before treatment and 4 weeks after treatment
Secondary outcomes:
Other outcomes:
Locations:
city: Banī Suwayf
country: Egypt
facility: Ababa physical therapy center
Study officials:
References:
Clinical trial NCT06890078: Optimizing the Diagnosis of Pneumocystis in Immunocompromised Patients
Official title: Optimisation du Diagnostic de Pneumocystose Chez Les Patients Immunodéprimés
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Pneumocystis
Immunocompromised Patients
Keywords: immunocompromised patients
pneumocystis
Lead sponsor: Assistance Publique - Hôpitaux de Paris
Sponsor class: OTHER
First posted: 2025-03-21
Enrollment: 240
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult patients with suspected pneumocystis

Brief summary: Evaluate new diagnostic methods using qPCR on non-invasive samples, compared with reference techniques for the positive diagnosis of pneumocystis (PcP) in immunocompromised patients


Eligibility criteria: Inclusion Criteria:

* adult patients with suspected pneumocystis
* with an indication for bronchial fibroscopy for BAL or induced sputum
* no opposition to the research from the adult patient or his or her next of kin research for patients unable to express their non-opposition

Exclusion Criteria:

* Pneumocystis treated for more than 72 hours
* pregnancy/breast-feeding
* adult patients deprived of liberty, protected

Primary outcomes:
measure: Pearson correlation coefficient
timeFrame: At inclusion
Secondary outcomes:
measure: Fungal load by qPCR
timeFrame: At inclusion
measure: Fungal load by serum PCR
timeFrame: At inclusion
measure: Beta D glucan blood levels
timeFrame: At inclusion
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT03121378: Multiple Electrode Aggregometry to Assess Platelet Function in Patients Undergoing Hip Joint Alloplasty With and Without Bone Cement
Official title: Multiple Electrode Aggregometry to Assess Platelet Function in Patients Undergoing Hip Joint Alloplasty With and Without Bone Cement
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Arthroplasty
Methylmethacrylate Embolism
Platelet Aggregation
Keywords: Hip Joint Alloplasty
Bone Cements
Impedance Aggregometry
Platelet Activation
Lead sponsor: Medical University of Warsaw
Sponsor class: OTHER
First posted: 2017-04-20
Enrollment: 36
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients undergoing hip arthroplasty

Brief summary: The aim of the study is to assess blood platelet function and activation in patients undergoing both cement and non cement hip joint total alloplasty. Bone cement is used as a special biomaterial to help fix a hip prosthesis in place but is associated with bone cement implantation syndrome causing such complications as hypotension, cardiac arrhythmias. The pathophysiology of bone cement implantation syndrome is not fully known but one theory supports formation of clots in the bloodstream. This directly would activate platelets but no such study has been performed in humans. As bone reaming could potentially cause platelet activation even without bone cement, the study involves a control group of patients undergoing non cemented joint alloplasty.


Eligibility criteria: Inclusion Criteria:

* Patients qualified for hip arthroplasty
* Signed consent for study
* No abnormality in coagulation screen
* Not taking regular antiplatelet medication except small dose of acetylsalicylic acid

Exclusion Criteria:

* Lack of consent
* Low platelet count (\<100 thousand) in standard preoperative full blood count
* On regular antiplatelet medication (except 75mg acetylsalicylic acid)

Primary outcomes:
measure: Change in platelet aggregation as expressed by height and slope of curve
timeFrame: Up to 30 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Warsaw
country: Poland
facility: I Department of Anesthesiology and Intensive Care Warsaw Medical University
state: Mazowieckie
Study officials:
References:
Clinical trial NCT04993378: Prospectively Predict the Efficacy of Treatment of Gastrointestinal Tumors Based on Peripheral Multi-omics Liquid Biopsy
Official title: A Clinical Study Initiated by Investigator:Prospectively Predict the Efficacy of Precise Treatment of Gastrointestinal Tumors Based on Peripheral Blood Multi-omics Liquid Biopsy
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Advanced Gastric Adenocarcinoma
Immunotherapy
Keywords: plasma-based liquid biopsy protein biomarker
extracellular vesicles
protein biomarker
Lead sponsor: Peking University
Sponsor class: OTHER
First posted: 2021-08-06
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: All patients in this study were enrolled by the Department of gastrointestinal oncology, Peking University Cancer Hospital \& Institute for conventional therapy or clinical trials

Brief summary: To vertify the function of EV-score on predicting \& monitoring immunotherapeutic outcomes of GC

Detailed description: Our previous work identified four plasma EV-derived proteins and combined them to generate a signature score that robustly predicting immunotherapeutic outcomes at baseline and dynamically monitoring disease progressions along with the whole treatment.

Hence in this stuty, we plan to recruit a prospective cohort to support our conclusions, and provide possible method to realize predicting and monitoring immunotherapeutic outcomes of GC.

Eligibility criteria: Inclusion Criteria:

* Having signed informed consent
* Age≥ 18 years old
* Histologically confirmed gastric adenocarcinoma
* Unresectable recurrent or metastatic disease
* Measurable disease according to the RECIST criteria
* Life expectancy of ≥3 month
* No prior chemotherapy of the study more than 4 weeks
* Immunotherapy regimens were included in the treatment

Exclusion Criteria:

* Other previous malignancy within 5 year
* Surgery (excluding diagnostic biopsy) within 4 weeks prior to study
* Pregnancy or lactation period
* Legal incapacity

Primary outcomes:
measure: EV-Score
timeFrame: EV-Score was detected, analysis and reported at the baseline of the treatment.
Secondary outcomes:
measure: Survival significance of EV-Score
timeFrame: up to 3 years
Other outcomes:
Locations:
city: Beijing
country: China
facility: Peking University Cancer Hospital & Institute
Study officials:
References:
Clinical trial NCT01216878: Bioequivalency Study of Losartan Potassium 100 mg Tablet Under Fed Conditions
Official title: A Single Dose, 2-Period, 2-Treatment Bioequivalency Study of Losartan Potassium Tablets 100 mg Under Fed Conditions
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hypertension
Lead sponsor: West-Ward Pharmaceutical
Sponsor class: INDUSTRY
First posted: 2010-10-07
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The objective of this study was to prove the bioequivalence of Losartan Potassium 100 tablet under fasted conditions.


Eligibility criteria: Inclusion Criteria:

* No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening

Exclusion Criteria:

* Positive test for HIV, Hepatitis B, or Hepatitis C.
* Treatment with known enzyme altering drugs.
* History of allergic or adverse response to losartan potassium or any comparable or similar product.

Primary outcomes:
measure: bioequivalence determined by statistical comparison Cmax
timeFrame: 15 days
Secondary outcomes:
Other outcomes:
Locations:
city: Springfield
country: United States
facility: BioKinetic Clinical Applications, Inc.
state: Missouri
Study officials:
affiliation: Bio-Kinetic Clinical Applications, Inc.
name: Dennis N. Morrison, D.O.
role: PRINCIPAL_INVESTIGATOR
References: